-
1
-
-
9144269708
-
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
-
Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
-
(2004)
Ann Intern Med
, vol.140
, pp. 85-93
-
-
Skinner, M.1
Sanchorawala, V.2
Seldin, D.C.3
Dember, L.M.4
Falk, R.H.5
Berk, J.L.6
-
2
-
-
11144358046
-
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
-
Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-8.
-
(2004)
Blood
, vol.103
, pp. 2936-2938
-
-
Palladini, G.1
Perfetti, V.2
Obici, L.3
Caccialanza, R.4
Semino, A.5
Adami, F.6
-
3
-
-
33846256126
-
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial
-
Sanchorawala V, Wright DC, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109:492-6.
-
(2007)
Blood
, vol.109
, pp. 492-496
-
-
Sanchorawala, V.1
Wright, D.C.2
Rosenzweig, M.3
Finn, K.T.4
Fennessey, S.5
Zeldis, J.B.6
-
4
-
-
33846258025
-
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
-
Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465-70.
-
(2007)
Blood
, vol.109
, pp. 465-470
-
-
Dispenzieri, A.1
Lacy, M.Q.2
Zeldenrust, S.R.3
Hayman, S.R.4
Kumar, S.K.5
Geyer, S.M.6
-
5
-
-
36349024733
-
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
-
Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351-8.
-
(2007)
Haematologica
, vol.92
, pp. 1351-1358
-
-
Kastritis, E.1
Anagnostopoulos, A.2
Roussou, M.3
Toumanidis, S.4
Pamboukas, C.5
Migkou, M.6
-
6
-
-
36348976450
-
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
-
Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007;110:3561-3.
-
(2007)
Blood
, vol.110
, pp. 3561-3563
-
-
Sanchorawala, V.1
Skinner, M.2
Quillen, K.3
Finn, K.T.4
Doros, G.5
Seldin, D.C.6
-
7
-
-
33644757671
-
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: A report from the European Group for Blood and Marrow Transplantation
-
Schonland SO, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G, et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood 2006;107:2578-84.
-
(2006)
Blood
, vol.107
, pp. 2578-2584
-
-
Schonland, S.O.1
Lokhorst, H.2
Buzyn, A.3
Leblond, V.4
Hegenbart, U.5
Bandini, G.6
-
8
-
-
0035119772
-
Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma
-
Kroger N, Kruger W, Renges H, Zabelina T, Stute N, Jung R, et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001;112:421-3.
-
(2001)
Br J Haematol
, vol.112
, pp. 421-423
-
-
Kroger, N.1
Kruger, W.2
Renges, H.3
Zabelina, T.4
Stute, N.5
Jung, R.6
-
9
-
-
23244448608
-
-
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79: 319-28.
-
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79: 319-28.
-
-
-
-
10
-
-
33646109316
-
Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma
-
Kroger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M, et al. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. Exp Hematol 2006;34:688-94.
-
(2006)
Exp Hematol
, vol.34
, pp. 688-694
-
-
Kroger, N.1
Zagrivnaja, M.2
Schwartz, S.3
Badbaran, A.4
Zabelina, T.5
Lioznov, M.6
-
11
-
-
34147144964
-
Reduced-intensity conditioning for myeloma: Lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
-
Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588-94.
-
(2007)
Blood
, vol.109
, pp. 3588-3594
-
-
Crawley, C.1
Iacobelli, S.2
Bjorkstrand, B.3
Apperley, J.F.4
Niederwieser, D.5
Gahrton, G.6
-
12
-
-
47149110690
-
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared to monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability
-
Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared to monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008;111:4700-5.
-
(2008)
Blood
, vol.111
, pp. 4700-4705
-
-
Bochtler, T.1
Hegenbart, U.2
Cremer, F.W.3
Heiss, C.4
Benner, A.5
Hose, D.6
|